DIA
Drug Information Association Logo

DIA Convenes Industry, Academia, and International Regulatory Leaders to Address the Challenges of Future Use Sampling in Clinical Trials

Horsham, PA, USA — Aug 31, 2011

DIA will convene global industry, regulatory and academic leaders to investigate the current barriers to the optimal collection of samples for future research related to drug response or disease characterization during the Improving Clinical Trial Sampling for Future Research from September 20-21, 2011 in Philadelphia, PA. Session topics will include:

  • Health Authority/National Ethics Committee Restrictions on Sample Collection
  • Retention and Exportation of Samples
  • Regulatory Restrictions on Data Collection, Access and Sharing
  • IRB/EC Perspectives on Sample Collection in Your Region
  • Patient Perspectives
  • Consent and Authorization for Future Use of Samples and Data

“During clinical drug development, the pharmaceutical industry commonly requests the collection of samples for future research in order to investigate important new emergent scientific findings on how drugs relate to human health and disease. These include studies to explore mechanisms of drug action, response to therapies, and adverse events or to research subpopulations that emerge during clinical trials,” says Program Chairperson Amelia Wall Warner, PharmD, RPh, Head, Clinical Pharmacogenomics and Clinical Specimen Management; Director, Late Stage Development, Merck Research Laboratories, Merck & Co., Inc. “This international conference will be divided into three working sessions to look at key issues for future use sample collection in Japan, Europe, the US, and Canada.”

Register for Improving Clinical Trial Sampling for Future Research.

 

 

###

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.